Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target Raised to $115.00

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price lifted by HC Wainwright from $100.00 to $115.00 in a report issued on Monday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q4 2027 earnings at $0.18 EPS, FY2027 earnings at ($3.35) EPS, FY2028 earnings at ($3.12) EPS, FY2029 earnings at ($0.80) EPS and FY2030 earnings at $4.64 EPS.

Other research analysts have also issued research reports about the company. Wall Street Zen raised Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings downgraded Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a report on Wednesday, May 20th. Morgan Stanley raised their target price on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the stock an “overweight” rating in a research report on Thursday, July 23rd. Chardan Capital lifted their target price on shares of Arrowhead Pharmaceuticals from $90.00 to $115.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Finally, Stifel Nicolaus started coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, July 14th. They issued a “buy” rating and a $98.00 price target for the company. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.08.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $86.22 on Monday. The stock’s 50-day moving average is $78.61 and its two-hundred day moving average is $70.41. The firm has a market cap of $12.14 billion, a price-to-earnings ratio of -40.10 and a beta of 1.26. Arrowhead Pharmaceuticals has a 1 year low of $15.01 and a 1 year high of $95.49. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.10) by $0.17. The business had revenue of $73.74 million during the quarter, compared to the consensus estimate of $73.84 million. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The business’s quarterly revenue was down 86.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.75 EPS. Analysts predict that Arrowhead Pharmaceuticals will post -3.08 earnings per share for the current year.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Hongbo Lu sold 2,970 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the sale, the director directly owned 52,012 shares of the company’s stock, valued at $3,998,682.56. This represents a 5.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. M&T Bank Corp lifted its stake in shares of Arrowhead Pharmaceuticals by 2,569.6% in the fourth quarter. M&T Bank Corp now owns 240,634 shares of the biotechnology company’s stock valued at $15,976,000 after purchasing an additional 231,620 shares during the period. Kornitzer Capital Management Inc. KS acquired a new position in Arrowhead Pharmaceuticals during the fourth quarter worth about $2,375,000. Siren L.L.C. increased its holdings in Arrowhead Pharmaceuticals by 7.7% in the first quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock valued at $101,290,000 after buying an additional 115,000 shares in the last quarter. Baader Bank Aktiengesellschaft acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $912,000. Finally, SBI Okasan Asset Management Co.Ltd. acquired a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $2,541,000. 62.61% of the stock is currently owned by hedge funds and other institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.